Galectin Therapeutics Inc
GALT3.619USD
-0.031-0.84%
Market hours （ET）Quotes delayed by 15 min
229.07MMarket Cap
LossP/E TTM
More Details of Galectin Therapeutics Inc Company
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
Company Info
Ticker SymbolGALT
Company nameGalectin Therapeutics Inc
IPO dateSep 04, 2002
CEOMr. Joel Lewis, CPA
Number of employees15
Security typeOrdinary Share
Fiscal year-endSep 04
AddressSuite 240
CityNORCROSS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code30071
Phone16786203186
Websitehttps://galectintherapeutics.com/
Ticker SymbolGALT
IPO dateSep 04, 2002
CEOMr. Joel Lewis, CPA
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Richard E. Uihlein
Mr. Richard E. Uihlein
Independent Chairman of the Board
Independent Chairman of the Board
10.34M
--
Mr. Joel Lewis, CPA
Mr. Joel Lewis, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
930.30K
-5.72%
Mr. Kevin D. Freeman
Mr. Kevin D. Freeman
Independent Director
Independent Director
467.01K
+1.08%
Dr. Gilbert S. Omenn, M.D., Ph.D.
Dr. Gilbert S. Omenn, M.D., Ph.D.
Independent Director
Independent Director
82.24K
--
Mr. Jack W. Callicutt, CPA
Mr. Jack W. Callicutt, CPA
Chief Financial Officer
Chief Financial Officer
67.70K
+40.46%
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Independent Director
Independent Director
60.61K
--
Dr. Khurram Jamil
Dr. Khurram Jamil
Chief Medical Officer
Chief Medical Officer
60.00K
-9.57%
Dr. Harold H. Shlevin, M.D., Ph.D.
Dr. Harold H. Shlevin, M.D., Ph.D.
Independent Director
Independent Director
15.21K
--
Dr. Benjamin S. Carson, Sr.
Dr. Benjamin S. Carson, Sr.
Director
Director
--
--
Ms. Elissa J. Schwartz, Ph.D.
Ms. Elissa J. Schwartz, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard E. Uihlein
Mr. Richard E. Uihlein
Independent Chairman of the Board
Independent Chairman of the Board
10.34M
--
Mr. Joel Lewis, CPA
Mr. Joel Lewis, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
930.30K
-5.72%
Mr. Kevin D. Freeman
Mr. Kevin D. Freeman
Independent Director
Independent Director
467.01K
+1.08%
Dr. Gilbert S. Omenn, M.D., Ph.D.
Dr. Gilbert S. Omenn, M.D., Ph.D.
Independent Director
Independent Director
82.24K
--
Mr. Jack W. Callicutt, CPA
Mr. Jack W. Callicutt, CPA
Chief Financial Officer
Chief Financial Officer
67.70K
+40.46%
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Dr. Gilbert F. (Gil) Amelio, M.D., Ph.D.
Independent Director
Independent Director
60.61K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Uihlein (Richard E)
16.34%
10X Fund, L.P.
9.36%
The Vanguard Group, Inc.
3.46%
BlackRock Institutional Trust Company, N.A.
2.11%
Osaic Holdings, Inc.
1.93%
Other
66.80%
Shareholders
Shareholders
Proportion
Uihlein (Richard E)
16.34%
10X Fund, L.P.
9.36%
The Vanguard Group, Inc.
3.46%
BlackRock Institutional Trust Company, N.A.
2.11%
Osaic Holdings, Inc.
1.93%
Other
66.80%
Shareholder Types
Shareholders
Proportion
Individual Investor
21.60%
Investment Advisor
12.44%
Corporation
9.36%
Investment Advisor/Hedge Fund
2.60%
Research Firm
0.20%
Bank and Trust
0.17%
Hedge Fund
0.03%
Pension Fund
0.02%
Venture Capital
0.02%
Other
53.56%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
173
29.39M
46.46%
-903.45K
2025Q1
175
29.27M
46.24%
-1.01M
2024Q4
167
29.61M
47.52%
-69.18K
2024Q3
148
29.06M
46.85%
-523.51K
2024Q2
138
28.80M
46.46%
+1.25M
2024Q1
119
26.89M
43.43%
-139.12K
2023Q4
120
26.57M
43.67%
-339.82K
2023Q3
131
28.59M
47.99%
+3.27M
2023Q2
140
24.60M
41.36%
-1.20M
2023Q1
165
24.44M
41.11%
-1.83M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Uihlein (Richard E)
10.34M
16.34%
--
--
Feb 28, 2025
10X Fund, L.P.
5.92M
9.36%
--
--
Feb 28, 2025
The Vanguard Group, Inc.
2.19M
3.46%
+54.90K
+2.57%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.34M
2.11%
-201.81K
-13.12%
Mar 31, 2025
Osaic Holdings, Inc.
1.22M
1.93%
+42.88K
+3.63%
Mar 31, 2025
Czirr (James C)
1.09M
1.72%
+323.13K
+42.20%
Jun 06, 2025
Lewis (Joel)
930.30K
1.47%
-56.42K
-5.72%
Mar 03, 2025
Geode Capital Management, L.L.C.
852.71K
1.35%
-17.88K
-2.05%
Mar 31, 2025
Eldred (Kary N.)
499.63K
0.79%
--
--
Feb 28, 2025
Freeman (Kevin D)
462.01K
0.73%
-220.37K
-32.29%
Feb 28, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
